NASDAQ : HKPD
Cellyan Biotechnology Co., Ltd — Key statistics
Healthcare · Pharmaceutical Retailers · Hong Kong
Last price 1.8538 USD (Oct 30, 2026, 2:56 PM EDT) · Market cap 2.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.33M |
| Enterprise Value | 3.36M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 817,499 |
| Shares Outstanding | 1.17M |
| Shares Change (YoY) | +60.21% |
| Shares Change (QoQ) | +97.27% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| Forward PS | n/a |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.86 |
| Quick Ratio | 1.69 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.51 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -15.59% |
| Return on Assets (ROA) | -5.64% |
| Return on Invested Capital (ROIC) | -9.46% |
| Return on Capital Employed (ROCE) | -10.42% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | -$103,269 |
| Employee Count | 11 |
| Asset Turnover | 1.21 |
| Inventory Turnover | 26.19 |
Taxes
| Measure | Value |
|---|
| Income Tax | 7,666 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -92.67% |
| 50-Day Moving Average | 3.05 |
| 200-Day Moving Average | 9.35 |
| Relative Strength Index (RSI) | 35.61 |
| Average Volume (20 Days) | 56,152 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 195,736 |
| Short Previous Month | 67,129 |
| Short % of Shares Out | 16.66% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 13.43M |
| Gross Profit | 1.39M |
| Operating Income | -1.00M |
| Pretax Income | -1.13M |
| Net Income | -1.14M |
| EBITDA | -918,373 |
| EBIT | -1.00M |
| Loss Per Share | -$1.39 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 221,841 |
| Total Debt | 1.26M |
| Net Cash | -1.04M |
| Net Cash Per Share | -$0.88 |
| Equity (Book Value) | 9.58M |
| Book Value Per Share | 8.16 |
| Working Capital | 9.14M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -751,602 |
| Capital Expenditures | -35,470 |
| Depreciation & Amortization | 86,536 |
| Net Borrowing | -630,225 |
| Free Cash Flow | -787,072 |
| FCF Per Share | -$0.67 |
Margins
| Measure | Value |
|---|
| Gross Margin | 10.32% |
| Operating Margin | -7.48% |
| Pretax Margin | -8.40% |
| Profit Margin | -8.46% |
| EBITDA Margin | -6.84% |
| EBIT Margin | -7.48% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -60.21% |
| Shareholder Yield | -60.21% |
| Earnings Yield | -70.18% |
| FCF Yield | -33.83% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.89 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |